Aura Biosciences Risk Report
Explore Aura Biosciences across six non‑financial risk dimensions:ESG, Workforce, News & Media, Cybersecurity, Legal & Regulatory, Operational. Unlock the full report, original sources and timelines, and enable continuous monitoring.
Summary
📜 Innovation & R&D
Aura Biosciences is at the forefront of cancer treatment development, specifically targeting choroidal melanoma and bladder cancer. The company is leveraging novel drugs and advance-stage trials to make significant impacts in the precision cancer treatment sector. With $151 million extended cash runway reported, they're poised for continued advancements and trial expansions.
- Positive results from phase 1 trial of bel-sar in non-muscle-invasive bladder cancer were presented 🗓 March 24, 2025.
- Aura announced additional data from ongoing phase 1 trial in bladder cancer as a late-breaking abstract at the European Association of Urology Congress 🗓 March 3, 2025.
- They secured $75 million in funding for precision cancer treatment 🗓 May 15, 2025.
- Their virus-based drug eradicated tumors in 4 out of 5 low-grade bladder cancer patients 🗓 October 17, 2024.
- Fast track designation granted by FDA for a new therapy for non-muscle invasive bladder cancer 🗓 July 7, 2022.
Profile
News & Media
Real‑time aggregation of trusted sources tracking company‑related events with sentiment and topic tags for rapid risk triage.
Sign up to unlock Aura Biosciences’s complete news feed with sentiment and topic tags.
View Full ReportEntity List
Continuous third‑party screening across global sanctions, enforcement, and watchlist sources with unified entity resolution and real‑time alerts.
| Name | Issuer | Status |
|---|---|---|
| ACF List of War Enablers | Anti-Corruption Foundation | |
| African Development Bank Debarred Entities | African Development Bank Group | |
| Argentina Members of Parliament | Honorable Cámara de Diputados de la Nación Argentina | |
| Argentina RePET Sanctions | Ministerio de Justicia | |
| Armenia Public Officials and Associates | Hetq Online | |
| Asian Development Bank Sanctions | Asian Development Bank | |
| Australian Sanctions Consolidated List | Department of Foreign Affairs and Trade | |
| Democratic People's Republic Of Korea (North Korea) Sanctions Regime | Department of Foreign Affairs and Trade | |
| Former Federal Republic Of Yugoslavia Sanctions Regime | Department of Foreign Affairs and Trade | |
| Iran Sanctions Regime | Department of Foreign Affairs and Trade |
Sign up to unlock Aura Biosciences’s sanctions, enforcement, and watchlist risk profile.
View Full ReportESG
Verification of declared ESG commitments and certifications with evidence links, score signals, and status updates across E, S, and G.
| Name | Status |
|---|---|
| Sustainable Finance Disclosure Regulation | |
| Global Reporting Initiative Standards | |
| EU Taxonomy Regulation | |
| EU Corporate Sustainability Reporting Directive | |
| California Transparency in Supply Chains Act | |
| EU Non-Financial Reporting Directive | |
| ISO 14001 | |
| Sustainability Accounting Standards Board Standards | |
| Task Force on Climate-related Financial Disclosures | |
| UN Guiding Principles on Business and Human Rights |
Sign up to unlock Aura Biosciences’s ESG commitments, certifications, and controversy signals.
View Full ReportCybersecurity
Verification of adherence to recognized security standards, mapping control coverage and gaps affecting third‑party and supply‑chain risk.
| Certification | Status |
|---|---|
| General Data Protection Regulation | |
| Digital Operational Resilience Act | |
| Cybersecurity Maturity Model Certification | |
| NIST Cybersecurity Framework | |
| NIST 800-53 Revision 5 | |
| California Consumer Privacy Act | |
| ISO/IEC 27001 | |
| Health Insurance Portability and Accountability Act | |
| Payment Card Industry Data Security Standard | |
| Federal Information Security Modernization Act |
Sign up to unlock Aura Biosciences’s security standards, control gaps, and exposure risks.
View Full ReportGet Aura Biosciences's full Non-Financial Risk Report
By signing up, you agree to our Terms and Privacy Policy.